Home Tags Pyxis Oncology

Tag: Pyxis Oncology

Pyxis Oncology to Prioritize Lead ADC Program

Clinical-stage Pyxis Oncology, a  company focused on developing antibody-drug conjugates (ADCs) and immune-oncology (IO) therapeutics to target difficult-to-treat cancers, is prioritizing the development of their investigational ADC, PYX-201,  a novel first-in-concept and first-in-class tumor stroma targeting ADC. Phase 1 trial progressing with fifth dose cohort at 3.6 mg/kg; data expected 1H 2024.

Pyxis Oncology Positions Itself at the Forefront of ADC Development with...

Pyxis Oncology, a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, and Apexigen, a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody therapeutics for oncology, confirmed that the companies have signed a definitive agreement by which Pyxis Oncology will acquire Apexigen in an all-stock transaction for an implied value of $0.64 per Apexigen share.

First Patient Dosed in Phase 1 Trial with Pyxis Oncology’s PYX-201

A first patient has been dosed in a Phase 1 trial of PYX-201, a novel antibody-drug conjugate (ADC) product candidate being developed by Pyxis Oncology and licensed from Pfizer targeting extra-domain-B (EDB) of fibronectin, a non-internalizing antigen, that is an integral component of the extracellular matrix in tumors. It is an alternatively spliced form of fibronectin with high expression in the extracellular matrix of neovascularized tissues and malignant cancer cells and minimally expressed in most normal adult tissues.

Pyxis Oncology to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary...

The US Food and Drug Administration (FDA) has cleared two Investigational New Drug (IND) applications from Cambridge, Massachusetts-based biotech Pyxis Oncology, allowing the company to...